Managers

Cowboy Ventures gallops to $93 mln for third fund

Cowboy Ventures has raised $93 million for its third fund, according to an SEC filing. The target is $95 million. Cowboy Ventures III will focus on backing U.S.-based seed-stage technology startups.

Akouos nabs $50 million Series A

Boston-based Akouos, a precision genetic medicine company, has raised $50 million in Series A financing. The lead investors were 5AM Ventures and New Enterprise Associates. Other investors in the round were Partners Innovation Fund, Sofinnova Ventures, RA Capital Management and Novartis Venture Fund.

Cybersecurity investor Ten Eleven raises $140 mln for growth fund, adds Temasek as LP

Burlingame, California-based cybersecurity-focused investor Ten Eleven Ventures announced it has raised $140 million for its second growth fund. The firm, managed by Alex Doll, a digital-security entrepreneur and son of DCM Ventures co-founder Dixon Doll, and investor Mark Hatfield, said it added several new investors into the fund, including Singapore LP Temasek. Ten Eleven said it will work with Temasek to expand geographically, including into Southeast Asia, where the firm says its portfolio companies are aiming to reach when they hit the point of scaling.

August Capital targets $250 mln for eighth fund

August Capital is seeking to raise $250 million for its eighth fund, according to an SEC filing. Based in Menlo Park, California, the venture firm is focused on information technology.

Colorado, North Carolina, Maryland see strong emerging market funding

VC performance improves in the first quarter

Karuna Pharmaceuticals nabs $42 mln Series A

Boston-based Karuna Pharmaceuticals, which is focused on targeting muscarinic receptors for treating disorders marked by psychosis and cognitive impairment, has secured $42 million Series A financing. The investors included ARCH Venture Partners.

Green Acre Capital raises $35 mln-plus for second cannabis fund

Canadian cannabis investment firm Green Acre Capital has launched its second fund, securing more than $35 million in lead commitments. Green Acre Capital Fund II was backed by Aphria Inc, York Plains Investment Corp, Brett Wilson, Craig Lothian and several other wealthy investors. Like Fund I, which raised $25 million last year, Fund II will invest in early- and growth-stage private companies in the medical and recreational cannabis industry. It will source opportunities in Canada and abroad. Based in Toronto and Calgary, Green Acre Capital is led by Managing Directors Matt Shalhoub and Tyler Stuart.

Impact Therapeutics scores $30 mln Series C

China-based Impact Therapeutics Inc, a developer of medicine that treats cancer and other life-threatening diseases, has closed $30 million in Series C financing. Decheng Capital led the round with participation from return backer Lilly Asian Ventures.

Georgian Partners closes fourth tech fund at $550 mln, continues hiring spree